Check-Cap Issues Letter To Shareholders (Full Letter)
Check-Cap Issues Letter To Shareholders (Full Letter)
致股東的支票上限函件 (全文)
Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ:CHEK), (NASDAQ:CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only patient-friendly preparation-free screening test to detect polyps before they may transform into colorectal cancer (CRC), today issued the following letter from its chief executive officer, Alex Ovadia, to its shareholders and the investment community:
Check-Cap Ltd.(以下簡稱“公司”或“Check-Cap”)(納斯達克代碼：CHEK)，一家推進C-®開發的臨牀階段醫療診斷公司(納斯達克代碼：CHEKZ)，這是第一種也是唯一一種對患者友好的免準備篩查測試，可以在息肉轉化為結直腸癌之前發現它們。該公司首席執行官亞歷克斯·奧瓦迪亞今天發表了以下致股東和投資界的信：
Dear Check-Cap Shareholders,
尊敬的Check-Cap股東們，
We have greatly appreciated your support throughout 2021, a year during which we have continued our progress as we prepare to initiate our U.S. pivotal study of C-Scan, including strengthening our...
我們非常感謝您在2021年期間對我們的支持，在這一年裏，我們繼續...
登入免費觀看全文
登入/註冊